🇺🇸 DORZAGLIATIN in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 14

Most-reported reactions

1. Hypoglycaemia — 3 reports (21.43%)
2. Dysarthria — 2 reports (14.29%)
3. Gait Disturbance — 2 reports (14.29%)
4. Aspartate Aminotransferase Increased — 1 report (7.14%)
5. Blood Glucose Decreased — 1 report (7.14%)
6. Chills — 1 report (7.14%)
7. Dermatitis Allergic — 1 report (7.14%)
8. Diabetes Mellitus Inadequate Control — 1 report (7.14%)
9. Diabetic Ketoacidosis — 1 report (7.14%)
10. Diabetic Neuropathy — 1 report (7.14%)

Source database →

Frequently asked questions

Is DORZAGLIATIN approved in United States?

DORZAGLIATIN does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for DORZAGLIATIN in United States?

Marketing authorisation holder not available in our data.